Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary) ; Secukinumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms MEASURE 3
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2022 Results of post-hoc pooled analysis of 3 secukinumab studies (MEASURE 2,-3 &-4) assessing -term NSAID-sparing effect of secukinumab over 4 years in patients with r-axSpA, published in the Rheumatology International.
    • 05 Jun 2021 Results of post-hoc pooled analysis of 6 studies (MEASURE 1-5 & PREVENT) presented at the 22nd Annual Congress of the European League Against Rheumatism.
    • 15 Mar 2021 Results of post-hoc pooled analysis from four clinical studies: NCT01358175, NCT01649375, NCT02008916 and NCT02159053 published in The Journal of Rheumatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top